Cellectar Biosciences Inc (CLRB) Annual Balance Sheets

Annual · GAAP · USD millions
Access CLRB quarterly Balance Sheets →
The data below summarizes Cellectar Biosciences Inc's balance sheet position from Dec 31 2021 to Dec 31 2025, enabling a period-by-period comparison of financial strength.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2025)
(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Assets
Cash & cash equivalent13.20
Cash & Short-term Investments13.00
Prepaid Expense And Other Assets Current0.84
Total Current Assets14.04
Equipment/Property/Plant Net0.55
Long-term investments0.00
Other Assets, Noncurrent0.39
Operating Lease Right Of Use Asset0.36
Total Assets14.98
Liabilities
Accounts Payable and Accrued Liabilities, Current LI4.42
Derivative Liability, Current DE0.23
Other Liabilities, Current0.00
Total Current Liabilities4.75
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
Operating Lease Liability Current0.10
Operating Lease Liability Noncurrent0.31
Total Liabilities5.06
Stockholders' Equity
Common Stock Value0.00
Additional Paid In Capital Common Stock277.15
Retained Earnings / Accumulated Deficit-269.13
Other Equity-1.38
Common Stockholder's Equity6.63
Preferred Stockholder's Equity0.52
Non-controlling interests & other1.38
Total Stockholder's Equity8.54
Liabilities & Stockholder's Equity14.98
4 historic quarters locked

Sign in to unlock the full Cellectar Biosciences Inc balance sheet history.

About Cellectar Biosciences Inc Annual Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-K filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001104659-26-023167

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.